Kovack Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Kovack Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64M	Buy	10,382 +2,743	+36%	+$371K	0.08%	253
2026 Q1	$978K	Sell	7,639 -138	-2%	-$17.2K	0.05%	374
2025 Q4	$948K	Buy	7,777 +4,158	+115%	+$477K	0.04%	398
2025 Q3	$363K	Sell	3,619 -1,199	-25%	-$108K	0.03%	413
2025 Q2	$400K	Sell	4,818 -541	-10%	-$43.2K	0.04%	387
2025 Q1	$435K	Sell	5,359 -787	-13%	-$70.3K	0.05%	337
2024 Q4	$553K	Buy	6,146 +1,597	+35%	+$155K	0.05%	286
2024 Q3	$449K	Sell	4,549 -705	-13%	-$69.3K	0.05%	328
2024 Q2	$487K	Buy	5,254 +1,292	+33%	+$116K	0.05%	306
2024 Q1	$376K	Sell	3,962 -2,257	-36%	-$209K	0.05%	307
2023 Q4	$555K	Sell	6,219 -10,025	-62%	-$744K	0.07%	278
2023 Q3	$1.19M	Buy	16,244 +1,422	+10%	+$114K	0.17%	130
2023 Q2	$1.23M	Buy	14,822 +11,404	+334%	+$954K	0.16%	134
2023 Q1	$260K	Buy	+3,418	New	+$284K	0.04%	444
2022 Q3	–	Sell	-11,112	Closed	-$825K	–	649
2022 Q2	$825K	Buy	+11,112	New	+$834K	0.11%	204
2017 Q1	–	Sell	-3,667	Closed	-$217K	–	328
2016 Q4	$217K	Buy	+3,667	New	+$226K	0.1%	219

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Kovack Advisors's XBI Position: Q2 2026 in Review

Kovack Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 36% in Q2 2026, buying an estimated $371K and bringing the position to 10,382 shares worth $1.64M. The position accounts for 0.08% of the portfolio, ranked #253.

Kovack Advisors first reported a position in XBI in Q4 2016 and has held it in 16 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Kovack Advisors held 10,382 shares of State Street SPDR S&P Biotech ETF worth $1.64M as of Q2 2026.
Kovack Advisors bought 2,743 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $371K.
State Street SPDR S&P Biotech ETF made up 0.08% of Kovack Advisors's portfolio in Q2 2026, its #253 holding.
Kovack Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 16 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.